Enveric Biosciences Selects Development Candidates from EVM301 Series Based on Potential to Minimize or Eliminate the Hallucinogenic Effect of Psychedelic-Derived CompoundsBusiness Wire • Tuesday
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of Glycosylated Psilocybin DerivativesBusiness Wire • 11/29/23
Enveric Biosciences Announces Manuscript Describing the Development of Lead Product Candidate, EB-373, to be Featured on the Cover of the Journal of Medicinal ChemistryBusiness Wire • 11/27/23
Enveric Biosciences Announces Presentation of Two Posters at Canadian Chemical Engineering Conference (CSChE 2023)Business Wire • 11/24/23
Enveric Biosciences Reports Third Quarter 2023 Corporate and Financial ResultsBusiness Wire • 11/13/23
Enveric Biosciences Receives Notice of Allowance from USPTO for Development of C4-Carbonothioate-substituted Tryptamine Derivatives for Novel Prodrug of PsilocinBusiness Wire • 10/31/23
Enveric Biosciences Initiates GLP Toxicology & Safety Pharmacology Studies for Lead Candidate EB-373, a Next Generation Psilocin Prodrug Targeting Psychiatric DisordersBusiness Wire • 10/18/23
Enveric Biosciences Announces Two Poster Presentations at the 6th Neuropsychiatric Drug Development SummitBusiness Wire • 10/11/23
Enveric Biosciences Announces its Psybrary™ Portfolio Now Totals Over 1000 Psychedelic-Inspired Therapeutic CandidatesBusiness Wire • 10/03/23
Enveric Biosciences Announces Publication of a Paper Describing a Novel Bioproduction Platform for Psychedelic-Inspired Drug Discovery in the Journal of Biological ChemistryBusiness Wire • 09/27/23
Enveric Biosciences Expands IP Portfolio with New U.S. Patent for Novel Carboxylated Psilocybin Derivatives Supporting its EVM301 Series of Drug CandidatesBusiness Wire • 09/20/23
Enveric Biosciences to Present Poster Highlighting EVM301 Series at the International Conference on Molecular Biology and Biochemistry 2023Business Wire • 09/18/23
Enveric Biosciences Files Provisional Patent Application for AI-based Computational Methods for Identifying and Optimizing Novel Tryptamine DerivativesBusiness Wire • 09/11/23
Enveric Biosciences Announces New U.S. Patent for C4-Carboxylic Acid-Substituted Tryptamine DerivativesBusiness Wire • 09/05/23
Enveric Biosciences to Present at H.C. Wainwright 25th Annual Global ConferenceBusiness Wire • 08/30/23
Enveric Biosciences Strengthens Intellectual Property Portfolio with New U.S. Patent for Tryptamine-derived ProdrugsBusiness Wire • 08/28/23
Enveric Biosciences Completes Manufacturing of EB-373 to Supply Drug Material for Completion of Preclinical ProgramBusiness Wire • 08/21/23
Enveric Biosciences Reports Second Quarter 2023 Corporate and Financial ResultsBusiness Wire • 08/14/23
Enveric Biosciences Reports Positive Results from Preclinical Studies Supporting Metabolic Profile of Lead Candidate EB-373Business Wire • 07/24/23
Enveric Biosciences Reports Positive Results from Animal Studies Demonstrating Oral Bioavailability and Well Tolerated Side Effect Profile for EB-373Business Wire • 07/17/23
Enveric Biosciences Announces Development of Phase 1-Ready Formulation for EB-373 and Initiation of Scaled Up ManufacturingBusiness Wire • 06/26/23
Enveric Biosciences to Present at H.C. Wainwright 4th Annual Neuropsychiatry Virtual ConferenceBusiness Wire • 06/12/23
Enveric Biosciences Announces Two Poster Presentations at the Canadian Chemistry Conference and Exhibition (CSC 2023)Business Wire • 06/07/23
Enveric Biosciences Receives Notice of Allowance from USPTO for EVM301 Series of Drug CandidatesBusiness Wire • 06/05/23